Unlocking the aggressive potential of ZNF217 Exon-4 Skipping isoform in breast cancer and its contribution to bone metastasis

Breast cancer remains a major health concern worldwide, with bone metastases presenting a significant threat to patient outcomes. Generation of aberrant splicing variants with oncogenic potential are involved in the development and progression of tumors. this study identifies ZNF217-ΔE4 as a new oncogenic splice variant in breast cancer mediating cell aggressiveness and bone marrow homing, as well as a new indicator of the development of bone metastases. ZNF217-ΔE4 thus represents a novel candidate therapeutic target and a new valuable biomarker in the management of breast cancers, particularly in patients with a higher risk of developing bone metastases